Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AM and PM Placebo Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPD503 in Combination With Psychostimulants

NCT00734578
View directory record Official record
Conditions
ADHD
Interventions
SPD503-AM, SPD503-PM, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Not applicable Interventional

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations

NCT03485131
View directory record Official record
Conditions
Auditory Hallucination, Schizophrenia
Interventions
Transcranial direct-current stimulation (tDCS), Placebo
Device
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 2, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders

NCT03764098
View directory record Official record
Conditions
Alcohol Use
Interventions
Guanfacine ER, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 2, 2026, 5:46 AM EDT
Not yet recruiting Not applicable Interventional

Chronic Pain Optimization and Management for Relief and Functionality With TEA in Cirrhosis

NCT07820917
View directory record Official record
Conditions
Cirrhosis
Interventions
Transcutaneous Electrical Acustimulation (TEA), Sham Transcutaneous Electrical Acustimulation (TEA)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 2, 2026, 5:46 AM EDT
Terminated Early Phase 1 Interventional

Vitamin D and Cocaine Administration

NCT04826133
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Calcitriol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
30 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Enteral Iron Supplementation in Critical Illness

NCT00450177
View directory record Official record
Conditions
Anemic, Critically Ill Patients
Interventions
Ferrous Sulfate, Placebo Oral Tablet
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 2, 2026, 5:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

NCT06853015
View directory record Official record
Conditions
SCI - Spinal Cord Injury
Interventions
Dalfampridine, Placebo, STDP stimulation, Exercise training
Drug · Other · Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 2, 2026, 5:46 AM EDT
Active, not recruiting Phase 2 Interventional Results available

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

NCT00859781
View directory record Official record
Conditions
Prostate Cancer
Interventions
177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

NCT02496767
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tirasemtiv, Placebo tablets
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supplement Combination on Stress and Sleep

NCT06889584
View directory record Official record
Conditions
Healthy
Interventions
All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin)), AM Active Supplement Combination (Ashwagandha and Rhodiola rosea), PM Active Supplement Combination (Magnesium threonate, L-theanine, and apigenin), AM and PM Placebo
Combination Product · Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 50 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 2, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional

Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction

NCT04383262
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Fosamprenavir Calcium, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 64 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

NCT00763061
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004% Ophthalmic Solution (Travatan), Timolol 0.5% Ophthalmic Solution (Timoptic)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women

NCT01598272
View directory record Official record
Conditions
Anti Aging
Interventions
Vitality product AM + Vitality product PM, Placebo
Dietary Supplement
Lead sponsor
Pharmanex
Industry
Eligibility
35 Years to 73 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents

NCT00258479
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
ModafinilNicotine Replacement Therapy, Modafinil
Drug
Lead sponsor
Catherine Martin, MD
Other
Eligibility
16 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

NCT02289846
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
IW-9179, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 2, 2026, 5:46 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Facilitating Adjustment to Simulated Jet Lag

NCT05382923
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorder, Jet Lag Type
Interventions
Bright Light, Bright Light + Exercise + Melatonin, Control
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

NCT00759941
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
35 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 2, 2026, 5:46 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19

NCT04912921
View directory record Official record
Conditions
Inflammation, COVID19
Interventions
palmitoylethanolamide, Placebo, Curcumin, Control (microcrystalline cellulose)
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma

NCT00604890
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
API 31510 3% Topical Cream, API 31510 1.5% Topical Cream, Placebo
Drug · Other
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 2, 2026, 5:46 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 2, 2026, 5:46 AM EDT
Suspended Phase 3 Interventional

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

NCT04363203
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Hydroxychloroquine, Azithromycin, Placebo oral tablet
Drug
Lead sponsor
Salomeh Keyhani MD
Federal
Eligibility
216 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

NCT01518972
View directory record Official record
Conditions
Alcohol Abuse, Posttraumatic Stress Disorder
Interventions
Prazosin, Placebo medication
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 2, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

NCT02465437
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
JBT-101, Placebo, Part B Open-Label Extension
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 2, 2026, 5:46 AM EDT